The EMPEROR-Reduced trial studied the effects of empagliflozin in patients with chronic heart failure with reduced ejection fraction. The trial included patients with NYHA class II-IV heart failure and an ejection fraction below 40% who were receiving standard guideline-directed medical therapy. Patients were randomly assigned to receive empagliflozin 10 mg daily or placebo and followed for a median of 16 months. The study found that empagliflozin reduced the risk of the composite primary outcome of cardiovascular death or hospitalization for heart failure compared to placebo.

1. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

2. EMPEROR-Reduced Trial Marta Cobo Marcos
2017-2019
M. Packer presentation ESC 2020

3. EMPEROR-Reduced Trial Marta Cobo Marcos
The study included patients with chronic HF with reduced ejection fraction
Key inclusion criteria:
• NYHA class II–IV with LVEF ≤40%
• Elevated NT-proBNP
• Guideline-recommended medication
stable ≥1 week prior to first visit
• eGFR ≥20 ml/min/1.73 m2
Inclusion Criteria
Key inclusion criteria:
• NYHA class II–IV with LVEF ≤40%
• Elevated NT-proBNP
• Guideline-recommended medication
stable ≥1 week prior to first visit
• eGFR ≥20 ml/min/1.73 m2

4. EMPEROR-Reduced Trial Marta Cobo Marcos
Empagliflozin 10 mg qd + SOC
Placebo qd + SOC
Median follow-up: ~16 months
30-day
post-
treatment
period
End of treatment
at 841 primary
outcome events
Trial design

5. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

6. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

7. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

8. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

9. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

10. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

11. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

12. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

13. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

14. EMPEROR-Reduced Trial Marta Cobo Marcos
M. Packer presentation ESC 2020

15. EMPEROR-Reduced Trial Marta Cobo Marcos
“La empagliflozina añadida al tratamiento médico
óptimo disminuye el riesgo de mortalidad
cardiovascular/hospitalización por IC en el paciente
con IC y FE reducida, además de disminuir la
progresión de enfermedad renal”
CONCLUSIONES